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Previewsthat human keratinocytes secrete IL-6
in response to Pam2Cys, and that
patients with AD display increases in
iNOS expressing MDSC populations in
their blood and skin compared to healthy
controls. However, the benefits ofMDSCs
in AD patients with S. aureus colonization
and persistent disease are unclear.
A greater understanding of the role
of S. aureus and diacylated ligands for
TLR2/6 heterodimers in AD progression
will likely require further exploration
combining more physiologically relevant
animal models with mechanism targeted
investigations in AD patients. The studies
presented here reveal intriguing and
previously unappreciated TLR2 and
TLR6-dependent ‘‘Toll-erance’’ mecha-
nisms in the skin that might be criticallyimportant in the interrelationship between
commensal bacteria and the cutaneous
immune response.REFERENCES
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Immunotherapy is revolutionizing the treatment of cancer patients, but the molecular basis for tumor
immunogenicity is unclear. In this issue of Immunity, Deng et al. (2014) andWoo et al. (2014) provide evidence
suggesting that dendritic cells detect DNA from tumor cells via the STING-mediated, cytosolic DNA sensing
pathway.Although the terms antigenicity and
immunogenicity are often used as syno-
nyms, they refer to different features of
the adaptive immune response. Antige-
nicity defines the capacity of an antigen
to bind specifically to lymphocyte recep-
tors, either expressed on the cell surface
or when released as antibodies after
B cell activation. Immunogenicity refers
to the ability of an antigen to prime either
T or B cells. Antigens can thus bind to a
T or B cell receptor, but to be consid-
ered immunogens, they must also trigger
an adaptive immune response by acti-
vating dendritic cells (DCs). In this issue
of Immunity, Deng et al. (2014) and
Woo et al. (2014) analyze the molecular
basis for such immunogenicity, pro-
viding insight into DC activation by
cancer.While there is agreement about the
existence of tumor-associated and even
tumor-specific antigens, the immunoge-
nicity of cancer is still debated. Somatic
mutations in cancer can generate new
antigens with a frequency varying more
than 1,000-fold between the lowest and
highest extremes across different cancer
histology types (Lawrence et al., 2013).
Melanoma has one of the highest rates
of mutation and is associated with anti-
tumor T cells in the blood or among tu-
mor-infiltrating leukocytes in patients, as
well as with serum immunoglobulin G
(IgG) antibodies against hundreds of tu-
mor antigens. Due to technical restraints,
the first molecularly defined tumor-asso-
ciated antigens (TAA) were shared,mostly
nonmutated ‘‘self molecules,’’ but iden-
tification of immune responses specificfor epitopes generated by mutations are
becoming more common.
Immunogenicity, on the other hand, is
both clinically and experimentally more
difficult to define (Blankenstein et al.,
2012). Some transplantable cell lines
and tumors induced by carcinogenesis
can prime the adaptive immune response,
which is then able to control initially tumor
growth and progressively select variants
escaping immune recognition by different
mechanisms (Schreiber et al., 2011).
However, sporadic, autochthonous tu-
mors can promote a response character-
ized by the induction of tumor-reactive
IgG antibodies, the expansion of unre-
sponsive (anergic) CD8+ T cell popu-
lations, and infiltration of T cells in
neoplastic lesions (Willimsky et al.,
2008). Some investigators consider thisovember 20, 2014 ª2014 Elsevier Inc. 679
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Previewsevidence as an indication that tumors can
be either immunogenic or not immuno-
genic, with some specific histotypes un-
able to generate an effective antitumor
immunity. However, because generation
of tumor-specific IgG requires the inter-
play between CD4+ T and B lymphocytes,
alternative explanations might be that
either some tumors elicit a prevalent
humoral response or they induce anergy
at either early or late time points during
their progression.
Despite the different views about tumor
immunogenicity, it is clear that in some
cancer patients there is an endogenous
antitumor lymphocyte repertoire, which
can be mobilized for therapy by immune
modulators. Recent approval by FDA of
clinical use of antibodies against check-
point blockade molecules to treat meta-
static cancer represents the long-awaited
confirmation that immunotherapy is a
powerful, antineoplastic treatment (Page
et al., 2014). Even though clear-cut im-
mune correlates have not been identified
in patients experiencing a therapeutic
benefit, it is commonly accepted that
these new drugs do not act on cancer
cells but rather block inhibitory signaling
mediated by the T cell surface inhibitory
molecules, such as cytotoxic T lympho-
cyte antigen 4 (CTLA-4) and programmed
death 1 (PD-1). The real event that will
change our views about cancer therapy
and promote a fast development of new
insights in immunotherapy of cancer is
the clinical evidence that some patients
are experiencing long-term survival,
sometimes only after repeated treatments
with these antibodies, which suggests
but does not prove the intervention of
slow rejection mechanisms proper of the
adaptive immune response (Page et al.,
2014).
Other forms of more conventional ther-
apies, such as chemotherapy and radia-
tion therapy, can also influence tumor
immunogenicity. Cancer cells dying
after contact with antineoplastic agents
either expose on their surface or release
damage-associated molecular pattern
molecules, such as calreticulin, ATP, and
high mobility group box 1 protein, with
potent stimulatory activity on DCs (Zitvo-
gel et al., 2013). This ‘‘immunogenic cell
death’’ primes T lymphocyte responses
by driving enhanced phagocytosis and
antigen presentation, DC maturation,
activation of NLRP3-inflammasome-680 Immunity 41, November 20, 2014 ª2014dependent release of IL-1b, and TLR4-
and Myd88-dependent inflammatory
response, with differences depending on
the chemical nature of the drug (Zitvogel
et al., 2013).
Because a fraction of patients treated
with immunotherapy does not experience
clinical benefits, it is important to better
understand the factors that regulate
either spontaneous immunogenicity or
immunogenicity induced by medical
treatments (iatrogenic immunogenicity).
Type I interferon (IFN), primarily com-
prising IFN-a and IFN-b, plays a role in
both spontaneous and iatrogenic immu-
nogenicity of tumors. Only when the type
I IFN receptor 1 (IFNAR1), recognizing
both IFN-a and -b, is engaged do CD8+
DCs accumulate within the tumor, cross-
present tumor antigens, and initiate an
adaptive immune response dominated
by CD8+ T cells, both in primary tumors
and after radiation therapy. Building on
these already published data, in this issue
of Immunity, Deng et al. and Woo et al.
link sensing of tumor-cell derived DNA
by the STING-mediated cytosolic DNA
sensing pathway to type I IFN production
in both spontaneous and iatrogenic
cancer immunogenicity. STING is a
signaling molecule in the innate response
to cytosolic nucleic acid ligands. Cyto-
solic detection of DNA by cGAMP syn-
thase (cGAS) catalyzes the generation
of 20 to 50 cyclic GMP-AMP (cGAMP),
which binds to STING allowing it to
recruit, phosphorylate, and activate
TANK-binding kinase 1 (TBK1) and inter-
feron regulatory factor 3 (IRF3). Within
the nucleus, IRF3 initiates a transcrip-
tional program leading to production of
type I IFN that, once released by DCs,
binds to its receptor, acting in autocrine
and paracrine fashion. Type I IFN-stimu-
lated DCs cross-present TAA and acti-
vate tumor-specific CD8+ T lymphocytes
(Figure 1).
These results have a potential transla-
tional impact. In fact, interference with
lymphocyte inhibitory pathways, such as
CTLA-4 and PD-L1-PD-1, was therapeuti-
cally ineffective in mice lacking STING,
indicating that STING pathway is also
important for checkpoint blockade thera-
pies (Woo et al., 2014). Moreover, the
STING activator cGAMP was unsuccess-
ful alone but synergized with radiation to
decrease tumor burden and increase sur-
vival in wild-type but not STING-deficientElsevier Inc.mice, designating cGAMP as a prospec-
tive drug to decrease tumor resistance
to radiation (Deng et al., 2014).
To complete the picture, it must be
pointed out that type I IFN can be also
released by tumor cells exposed to
anthracyclines, which activate a circuit
leading to RNA recognition by TLR3within
the same tumor cells, release of type I IFN,
and downstream production of the che-
mokine CxCL10 (Sistigu et al., 2014).
Thus, the autocrine and paracrine activity
of IFN also contributes to in vivo chemo-
therapy mechanism of action by acti-
vating the adaptive immunity (Sistigu
et al., 2014).
These studies by Deng et al. and Woo
et al. raise several unanswered questions.
It appears that cancer cell DNA itself is
not more immunogenic than DNA from
noncancerous cells, as similar amounts
of IFN-b were produced after transfection
of DCs with DNA isolated from normal
splenocytes, provided that the DNA is
mixed with liposomes to allow delivery
to the cytosol (Woo et al., 2014). However,
injection of splenocytes in the subcutane-
ous space is not sufficient to activate the
STING-dependent cascade (Woo et al.,
2014), indicating that cell death due to
experimental protocols is not the contrib-
uting factor and some unknown features
related to neoplastic cell transformation
and demise are instead essential. More-
over, it is also unclear how DNA is gaining
access to DC cytosol. Although some
evidence is presented for the role of
phagocytic activity after radiation therapy
(Deng et al., 2014), how DNA is trans-
ferred from untreated tumor cells to DCs
remains a mystery.
How can tumors, either spontaneously
or in response to therapy, overcome the
tolerance circuits that normally restrain
the innate response to nucleic acids?
Studies of autoimmune diseases, in
which continuous triggering of immune
responses to self-antigens can sustain
severe tissue destruction, might provide
some clues. Systemic lupus erythema-
tous (SLE) is an autoimmune disease
characterized by the presence of patho-
genic autoantibodies recognizing dou-
ble-stranded DNA and small nuclear
ribonucleoproteins. Type I interferon,
released by plasmocytoid DCs, plays a
central role in SLE pathogenesis by
fueling self-sustaining loops that pro-
gressively hamper peripheral immune
Figure 1. Spontaneous and Iatrogenic Tumor Immunogenicity Require STING and Type I IFN
After tumor implantation or radiation therapy, tumor-derived DNA can access the DC cytosol and bind
cGAS to activate STING-mediated Ifnb transcription. 2030cGAMP is generated by cGAS from the sub-
strates ATP and GTP and, in turn, binds to and activates STING dimers, inducing phosphorylation of
TBK-1 and IRF3. Nuclear translocation of phosphorylated IRF3 controls IFN-b transcription. After binding
to its receptor, IFN-b renders DCs competent to present tumor antigens and prime CD8+ T lymphocytes.
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Previewstolerance and maintain disease activity
(Crow, 2014). However, type I IFN cooper-
ates with other immune mechanisms,
such as impaired clearance of immune
complexes and apoptotic material due
to defect in complement proteins. More-
over, subtle DNA modifications could be
required to increase DNA immunoge-
nicity. In fact, oxidized DNA generated
by cellular oxidative damage is protected
from 30 repair exonuclease 1-mediated
degradation and thus more prone to
activate STING pathway in SLE (Gehrkeet al., 2013). Defining better the molecular
elements that contribute to sustained
activation of innate and adaptive immu-
nity by DNA in the context of autoimmu-
nity might provide insight into innate
immune sensing pathways in the context
of cancer immunity. These findings might
also help to enlarge the fraction of pa-
tients who respond to immunotherapy
with prolonged control of the tumor.
Indeed, enhancing the immunogenicity
of their cancers might expand the lym-
phocyte repertoire that is then unleashedImmunity 41, Nby interference with checkpoint blockade
pathways.
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